David Hernández

30y - Radiation Oncologist👨🏽‍⚕️🇲🇽

[Advances, an ASTRO Journal @Advances_ASTRO]

New in Advances in Radiation Oncology:

A patterns-of-practice survey of prostate SABR across Australia and New Zealand, including 53 GU radiation oncologists from 31 institutions.

Key finding: 77% of respondents offer prostate SABR as standard of care. The dominant regimen was 40 Gy to the CTV and 36.25 Gy to the PTV in 5 fractions, broadly aligned with PACE-B. Practice remained variable regarding focal boost, offered by 19 respondents, as well as IPSS and prostate-volume cutoffs (>100 cc), PTV margins, and urethral management.

Why it matters: This is a rare real-world snapshot of how phase 3 evidence is translated into routine clinical practice. The findings will directly inform the bi-national FROGG prostate SABR guidelines.

Important caveat: The response rate was 28%, practices were self-reported, and non-adopters may be underrepresented. Access and cost also matter. Patient out-of-pocket funding for planning MRI was reported by 68% of respondents.

Bottom line: Adoption is broad and generally trial-concordant, but important variation remains. Expertise and access to motion-management technology were the leading barriers among non-adopters, areas that guidelines and structured upskilling may help address.

@ASTRO_org #RadOnc #OncTwitter #PCSM

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 Top 10 Tips for Stereotactic Body Radiation Therapy Contouring and Planning in Oligometastatic Disease: Lessons Learned From the UK SBRT QA Program ☢️
🔗 https://t.co/WkZDZSoA4I @OncoAlert #OncoAlertAF @IJROBP @fifimcdrmh @royalmarsdenNHS 
🔹Standardize definitions.
🔸 Optimize use of supporting imaging.
🔹 Motion management.
🔸 Optimize patient preparation.
🔹 Use all available TPS tools to optimize contouring.
🔸 Check auto-contouring output.
🔹 Appropriate use of OAR dose-volume constraints.
🔸 Maximize PTV coverage.
🔹 Conform tightly to the PTV.
🔸 Managing multiple lesions.

[David Palma, MD, PhD @drdavidpalma]

If you're interested in SABR, check out this interview with 3 of the OG SABR pioneers in the @ijrobp special issue: Drs. Hiroshi Onishi, Suresh Senan, and Robert Timmerman.

https://t.co/y8zR2jssti

[Dr. Nina Niu Sanford @NiuSanford]

Here is Version 2.0 of when to hold systemic tx during RT. Updated & w 3 additional drug categories (ADCs, CDK4/6 inhibitors, PARPi).

More details on newer drugs in 🧵 below.

Please use this version as reference & thanks for all input/experience crowdsourcing! (1/3)

[JAMA Network Open @JAMANetworkOpen]

1 in 3 academic physicians report they are considering leaving their institution within 2 years. Burnout and lack of professional fulfillment were associated with intention to leave; a comprehensive approach will be needed to reduce physician turnover. https://t.co/gD3o1U0Oj5

[Dr. Nina Niu Sanford @NiuSanford]

Rad onc = #1 for professional fulfillment 🙌🏽

[CA: A Cancer Journal for Clinicians @CACancerJournal]

Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT & SBRT. Multidisciplinary care, imaging, and innovation are key.

#OpenAccess review by Andratschke et al:
https://t.co/T41ik4rEsa

@OncoAlert #RadOnc

[Dr. Nina Niu Sanford @NiuSanford]

In RAPIDO, higher LRR w short course TNT confined to pts undergoing sphincter-preserving surg (12 v 5%), w distal resection margin <1cm as predictor.

Suggests need to re-eval safe margin & consider basing surg off original tumor extent.

Caveat: post hoc, exploratory analysis.

[Kristina Jankovic, MD @JankovicK]

INTERLACE or KEYNOTE-A18 for #CervicalCancer ? 🤔

It’s all about patient selection, risk profile, safety and clinical context💡

@OncoAlert

[SOMERA Sociedad Mexicana de Radioterapeutas @somera_mx]

¡ #Invitación! 📷
Los invitamos cordialmente a nuestra próxima sesión mensual SOMERA INTERNACIONAL donde abordaremos un tema muy importante y actual:
RADIOTHERAPY FOR THE MANAGEMENT OF LUNG CANCER: ADVANCES, INEQUALITIES, AND PROSPECTS.

📷 Registro gratuito:
https://t.co/l1YCjyfD6j
También transmisión en vivo a través de nuestro canal de Youtube: @someramexico01

Con SOMERA, cada paso en el conocimiento es un paso hacia una mejor atención.
#SOMERA #Rt #Radioterapia #SesiónSOMERAInternacional #Salud #PrevenciónEsSalud

[Elekta @Elekta]

Luna, a 9-year-old Husky, was paraplegic from a spinal tumor. After receiving SRT (20.01 Gy in 3 fx), she responded well and can walk again. Although Luna is still receiving chemo, she continues to do well. Learn more about RT for pet cancer ➡️ https://t.co/jrEBr6bhyl 🐾

[Travis Chapman @Travispaints]

I painted the legend, “Back Up Terry!”

[El Ranchero Loco ® @EIRancheroLoco]

Nada más porque trae lentes me di cuenta que no es el wolverine original. 🙂

[Angel Montero Luis @Monthy_A]

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy | New England Journal of Medicine #radonc #bcsm https://t.co/mVq6xAAN2T

[European Association of Urology (EAU) @Uroweb]

🧾 New Cheat Sheet on Prostate Cancer Treatment by Stage

🔹 Low-risk: Active surveillance; avoid ADT
🔹 Intermediate-risk: Surgery or RT; ADT case-based
🔹 High-risk: Surgery/RT + long-term ADT

#EAUguidelines #ProstateCancer

Download Cheat Sheet here:
https://t.co/IvTGHuFWt6

[Icro Meattini @Icro_Meattini]

Regional nodal irradiation in negative nodal status and after primary systemic therapy - amazing teaching lecture by Philip Poortmans and Liesbeth Boersma #ESTRO25

#radonc #breastcancer @OncoAlert #OncoAlert

[Krishan Jethwa @KrishanJethwa]

🔥ACRO ROVER- Upper GI🔥

Localized Esophagus Adenocarcinoma in 5 minutes, Check it out!
@ACROresident @ACRORadOnc @RadoncROVER @ARRO_org @MayoRadOnc @NiuSanford
1/

[Matthias Guckenberger @Mat_Guc]

Must read clinical trials in the field of #SBRT 2024

Please complement the list, to allow us staying up-to-date !

[Priyamvada Maitre @docpriyamvada]

#ASTRO24 Presidential symposium
Advances in #BladderPresevation by @l_ballas
🟢Decades of data behind ☢️ for #bladdercancer
🟢Outcomes Are SIMILAR 🔪vs☢️ (Zlotta, Dutch)
🟢NACT adds to benefit, will IO too?